top of page
January 31, 2022
Elusys Finalizes HHS Contract to Deliver ANTHIM® to the U.S. Department of Health and Human Services
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023
January 31, 2022
Elusys Finalizes HHS Contract to Deliver ANTHIM® to the U.S. Department of Health and Human Services
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023
December 2, 2020
Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax
December 2, 2020
Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax
October 8, 2020
Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax
European Commission Decision Anticipated in November 2020
October 8, 2020
Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax
European Commission Decision Anticipated in November 2020
News & Media
Newsletter Signup
Be the first to receive the latest news and updates.
bottom of page